Saatja:
[email protected]
Saaja: "Info - SOM" <
[email protected]>
Teema: Question regarding the treatment of rare disease
Kuupäev: 2025-11-04 09:23
Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga.
Tundmatu saatja korral palume linke ja faile mitte avada.
Dear Mr., Ms.,
The National Assembly of the Republic of Slovenia is preparing a comparative
analysis of the treatment of rare diseases in various Member States of the
European Union, including Estonia. Currently, as part of the legislative
process, a broad discussion is underway in Slovenia regarding the creation
of a special fund for the treatment of rare diseases, which would be
intended for individuals with rare diseases.
That is why we are interested in how the treatment of rare diseases for
individuals is carried out in Estonia, namely, who are the beneficiaries of
receiving funds (patients, treatment providers, intermediaries) for
treatment, to what extent the treatment of an individual patient is financed
and how are the beneficiaries of the aforementioned funds determined? Are
the funds for covering the treatment of rare diseases provided within the
framework of health insurance funds or within other budget items? In
addition to the above, we are interested in whether any initiative has been
made in the past to establish a special fund for financing the treatment of
rare diseases.
We thank you in advance for your answers, as they will be of great help to
us in understanding in more detail the situation in Estonia.
Best regards,
Aldijana Ahmetović
Raziskovalni oddelek
Šubičeva 4, 1000 Ljubljana, Slovenija | T:+386 1 478 9429 | E:
<mailto:
[email protected]>
[email protected] | Splet:
<http://www.dz-rs.si/> www.dz-rs.si
Mislimo zeleno. Hvala, ker tega sporočila niste natisnili.
Think green before printing!